US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Company Overview - Intellia Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with its late-stage clinical trial for an experimental gene therapy targeting heart disease [1]. Industry Impact - The lifting of the clinical hold by the FDA is a significant development for the gene therapy sector, indicating regulatory support for innovative treatments in the healthcare industry [1].